Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 22;38:424. doi: 10.1186/s13046-019-1425-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Indirect IF micrographs demonstrating nuclei (blue) and differences in IF immunoreactivity (green) to antibodies against TrkA (anti-TrkA) and Y490 phosphorylated TrkA (anti-pY490 TrkA) in: a) sequential recurrent stage IV MCCs (patients P.1 (i-iv), contemporary recurrent stage IV MCCs (patients P.2 (i-iii) and P4 (i)), and individual stage 1-IV MCPyV large T-antigen positive (MCPyV⁺) MCCs (patients P.4 (i) and P.5–10) and b) in an MCPyV negative (MCPyV⁻) MCC (patient P.11), 2 MCPyV negative BCCs (patients, P.12 and P.13), 1 MCPyV large T-antigen positive BCC (patient P.14), 3 MCPyV negative SCCs (patients P.15–17) and 2 MCPyV negative normal skin samples (NS1 and 2) (bar = 50 μm)